Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
218estimated
Sites
5
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-17 | actual | When the study began enrolling |
| Primary completion | 2026-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Biological: Ixekizumab
Primary outcomes
what the primary-completion date above is the date OFAUC0-inf
measured Day 85
Cmax
measured Day 85
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed